Bozitinib (Synonyms: PLB-1001; CBT-101; Vebreltinib) |
Katalog-Nr.GC38894 |
Bozitinib (PLB-1001) ist ein hochselektiver c-MET-Kinase-Inhibitor mit PermeabilitÄt der Blut-Hirn-Schranke. Bozitinib (PLB-1001) ist ein ATP-kompetitiver niedermolekularer Inhibitor, der an die konventionelle ATP-Bindungstasche der Tyrosinkinase-Superfamilie bindet.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1440964-89-5
Sample solution is provided at 25 µL, 10mM.
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
Bozitinib (PLB-1001) (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3, has a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways. Western Blot Analysis[1] Cell Line: Human astrocytes (HA) cells
[1]. Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *